Loading clinical trials...

A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL | Clinical Trials | Clareo Health

RECRUITINGPHASE3

A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL

A Randomized Controlled Clinical Trial Comparing Chidamide,Carmustine,Etoposide,Cytarabine and Melphalan With BEAM Regimen Combined With Autologus Hematopoietic Stem Cell Transplantation for the Treatment of Newly Diagnosed PTCL

NCT05931263•The First Affiliated Hospital with Nanjing Medical University

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to compare Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL. The main question it aims to answer are: •Whether Chi-BEAM improves patient survival compared to BEAM group Participants will be given BEAM or Chi-BEAM before ASCT. Researchers will compare the efficacy and safety of the two groups.

Detailed Description

This is a prospective, multicenter, randomized controlled, open trial. The primary endpoint was 2-year PFS The secondary endpoint was： 2-year overall survival (OS). CR rate at 3 months post-transplant evaluation Hematopoietic reconstitution time Non-recurrent mortality (NRM)

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Pathologically diagnosed patients with newly treated PTCL (including NT/ K-cell lymphoma), except for ALK (+), have CR or PR after first-line treatment;
•2. Renal function needs to be satisfied: creatinine clearance ≥80ml/min, creatinine less than 160μmol/L; Liver function requirements: ALT and AST≤2 times the upper limit of normal; Total bilirubin ≤2 times the upper limit of normal; Lung function should meet: FEV1, FVC, DLCO≥50% predictive value; Cardiac function must be satisfied: left ventricular ejection fraction ≥50%, asymptomatic arrhythmia.
•3. Age between 18 and 65 years old, male and female;
•4. ECOG physical strength score 0-1;
•5. Neutrophil absolute value ≥1.5×109/L, platelets ≥ 70×109/L, hemoglobin ≥ 90g/L; Number of CD34+ cells ≥ 2.0×106/kg body weight;
•6. Expected survival time ≥3 months;
•7. Voluntarily sign written informed consent.

Exclusion Criteria

•1. Lymphoma involving the central nervous system
•2. Active hepatitis B or C virus infection;
•3. Active infection;
•4. HIV infected persons;
•5. Evidence of cirrhosis or liver fibrosis;
•6. Ecg showed QTc \> 500ms;
•7. Persons with mental disabilities/unable to obtain informed consent;
•8. Patients with drug or chronic alcohol abuse that may affect the evaluation of study results;
•9. Pregnant and lactating women and women of childbearing age who do not want to take contraceptive measures;
•10. The researcher determines that it is not suitable to participate in this study

Locations (1)

Hematological Department, People's Hospital of Jiangsu Province

Nanjing, Jiangsu, China

Key Dates

Start Date

June 1, 2023

Primary Completion Date

February 1, 2026

Completion Date

February 1, 2028

Last Updated

July 5, 2023

Enrollment

104

ESTIMATED participants

Conditions

Newly Diagnosed Peripheral T-cell Lymphoma

Interventions

C-BEAM Regimen

DRUG

BEAM Regimen

DRUG

Contacts

wei xu

CONTACT

86-25-68302182 xuwei10000@hotmail.com

CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma

NCT05896813

Newly Diagnosed Peripheral T-cell Lymphoma

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 5, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions